Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SMMT 
Summit Therapeutics PLC (SMMT)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: SMMT (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.39
1 Year Target Price $31.39
| 7 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 101.41% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.56B USD | Price to earnings Ratio - | 1Y Target Price 31.39 |
Price to earnings Ratio - | 1Y Target Price 31.39 | ||
Volume (30-day avg) 10 | Beta -1.55 | 52 Weeks Range 15.55 - 36.91 | Updated Date 11/4/2025 |
52 Weeks Range 15.55 - 36.91 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-28 | When Before Market | Estimate -0.1032 | Actual -0.2315 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -152.88% | Return on Equity (TTM) -292.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15210891044 | Price to Sales(TTM) 753.9 |
Enterprise Value 15210891044 | Price to Sales(TTM) 753.9 | ||
Enterprise Value to Revenue 6425.28 | Enterprise Value to EBITDA -5.32 | Shares Outstanding 744442538 | Shares Floating 102546960 |
Shares Outstanding 744442538 | Shares Floating 102546960 | ||
Percent Insiders 86.05 | Percent Institutions 13.63 |
Upturn AI SWOT
Summit Therapeutics PLC
Company Overview
History and Background
Summit Therapeutics PLC is a biopharmaceutical company historically focused on developing therapies for Duchenne muscular dystrophy and other unmet medical needs. The company was founded in 2003 and has undergone strategic shifts, including a recent focus on oncology.
Core Business Areas
- Oncology: Focuses on the discovery, development, and commercialization of innovative medicines for the treatment of cancer. The primary asset is ivonescimab.
Leadership and Structure
Summit Therapeutics PLC's leadership team consists of experienced professionals in drug development and commercialization. The organizational structure is aligned with its focus on oncology.
Top Products and Market Share
Key Offerings
- Ivonescimab: A novel bispecific antibody targeting VEGF and Ang-2 for the treatment of solid tumors. Ivonescimab is currently in clinical trials. Competitors include existing VEGF and Ang-2 inhibitors and bispecific antibodies under development by companies like Roche (RHHBY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Oncology is a major area of focus due to the high unmet medical need.
Positioning
Summit Therapeutics PLC is positioning itself as an innovative oncology company with ivonescimab as its lead asset. Its competitive advantage lies in the bispecific nature of the antibody and its potential to address resistance mechanisms to existing therapies.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is substantial, estimated to be hundreds of billions of dollars annually. Summit Therapeutics PLC is positioned to capture a portion of this TAM with ivonescimab, depending on its clinical success and commercialization strategy.
Upturn SWOT Analysis
Strengths
- Novel bispecific antibody (ivonescimab)
- Experienced management team
- Focus on oncology
Weaknesses
- Reliance on a single lead asset
- Limited commercialization experience
- High cash burn rate
- Requires FDA approval
Opportunities
- Successful clinical trials for ivonescimab
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or in-licensing
- Potential for ivonescimab to become a blockbuster drug
Threats
- Clinical trial failures
- Competition from other oncology therapies
- Regulatory hurdles
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- RHHBY
- REGN
- MRK
Competitive Landscape
Summit Therapeutics PLC is a smaller player in the oncology market compared to larger pharmaceutical companies. Its success depends on demonstrating the clinical superiority of ivonescimab.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's development stage and strategic shifts.
Future Projections: Future growth is dependent on the successful development and commercialization of ivonescimab. Analyst projections vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing ivonescimab through clinical trials and exploring potential partnerships.
Summary
Summit Therapeutics PLC is a clinical-stage biopharmaceutical company focused on oncology. Its fortunes hinge on the success of ivonescimab. The company's financial health depends on securing additional funding. Summit faces significant competition in the oncology space from established players.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biopharmaceutical companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Summit Therapeutics PLC
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2015-03-05 | Co-CEO & Executive Chairman Mr. Robert W. Duggan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 159 | Website https://www.smmttx.com |
Full time employees 159 | Website https://www.smmttx.com | ||
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.